MEDG Medgenics(Regs)

Medgenics Inc
18 March 2008

                                Medgenics, Inc.
                         ("Medgenics" or the "Company")


  MEDGENICS CONSOLIDATES CORPORATE AND R&D OPERATIONS INTO NEW OFFICE FACILITY

Misgav, Israel and London, UK - 18 March 2008 - Medgenics (AIM: MEDG), the
US-incorporated biopharmaceutical company developing the 'biopump'
sustained-action protein therapy for the treatment of chronic diseases, has
completed its move to a new facility on the Teradion Business Park in Misgav,
Israel. The new facility brings together Medgenics' corporate operations with
larger R&D laboratories on one site.

At the same time, the Company has more than doubled its scientific and
engineering staff from four at Admission to ten now, in accordance with its plan
and preparation for the Phase I/II clinical trial for EPODURE: its lead product
in development to deliver a sustained therapeutic dose of erythropoietin (EPO)
for the long-term treatment of anaemia. Subject to regulatory approval, EPODURE
is on schedule to begin Phase I/II clinical trials in mid 2008 and preliminary
data are anticipated from these trials within 3-5 months of trial commencement.

Dr. Andrew Pearlman, Medgenics' CEO, said:

"Medgenics is really gearing up for the start of our Phase I/II clinical trial
with EPODURE as a potential new therapy for anaemia, which is due to begin mid
year. The new additions to the development team for EPODURE are in keeping with
our plan and schedule as we advance toward this important trial. The move brings
the whole Company together under one roof for the first time, which will be
important in enhancing communication between the various departments as we move
forward into this exciting period for the Company."

Medgenics' new mailing address is:
Teradion Business Park
PO Box 14
Misgav, 20179, ISRAEL
Tel: +972-4-902-8900
Fax: +972-4-999-0114


                                      ####


For further information, contact:

Medgenics, Inc.                                   Phone: +972 4 902 8900
Dr. Andrew L. Pearlman

Citigate Dewe Rogerson                            Phone: +44 207 638 9571
Dr. Mark Swallow
Jonathan Shillington (Global Consulting Group)

Blomfield Corporate Finance Limited               Phone: +44 207 512 0191
James Pinner
Alan MacKenzie


NOTES TO EDITORS:

About Medgenics

Medgenics, Inc. is a biopharmaceutical company developing its unique
tissue-based Biopump platform technology to provide sustained-action protein
therapy for the treatment of a range of chronic diseases.

Medgenics currently has two products in development based on this technology:
     
*    EPODURE - producing erythropoietin (EPO) to treat anaemia
*    INFRADURE - producing interferon-alpha (IFN-a) to treat hepatitis C

The Company has demonstrated proof of principle of the Biopump treatment
procedure in a clinical trial using a short-acting version of EPODURE in anaemic
patients. A long-acting version of EPODURE, designed to produce and deliver a
therapeutic dose of EPO steadily for six months or more, is scheduled to enter
Phase I/II trials in mid-2008. The Company plans to follow with clinical trials
of INFRADURE in 2009.

Medgenics intends to develop its innovative products and bring them to market
via multiple strategic partnerships with major pharmaceutical and/or medical
device companies, starting with EPODURE and INFRADURE.

Beyond these, Medgenics plans to develop and/or out-license a pipeline of future
Biopump products targeting the large and rapidly growing global protein therapy
market, which is forecast to reach US $87 billion by 2010. Other potential areas
include multiple sclerosis (interferon-b), haemophilia (Factor XIII),
paediatric growth hormone deficiency (human growth hormone) and diabetes
(insulin).

Founded in 2000, Medgenics is a US-incorporated company with major operations in
Misgav, Israel. Medgenics was admitted to AIM in December 2007 (AIM: MEDG).

www.medgenics.com

CAUTIONARY NOTICE REGARDING FORWARD-LOOKING STATEMENTS

This release contains forward-looking statements, which include all statements
other than statements of historical fact, including (without limitation) those
regarding the Company's financial position, business strategy, plans and
objectives of management for future operations. These statements relate to
future events, prospects, developments and strategies. Forward-looking
statements are sometimes identified by their use of the terms and phrases such
as "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning,
"expect," "believe," "will," "will likely," "should," "could," "would," "may" or
the negative of such terms and other comparable terminology. All such
forward-looking statements are based on current expectations and are subject to
risks and uncertainties. Should any of these risks or uncertainties materialize,
or should any of the Company's assumptions prove incorrect, actual results may
differ materially from those included within these forward-looking statements.
Accordingly, no undue reliance should be placed on these forward-looking
statements, which speak only as of the date made. The Company expressly
disclaims any obligation or undertaking to disseminate any updates or revisions
to any forward-looking statements contained herein to reflect any change in the
Company's expectations with regard thereto or any change in events, conditions
or circumstances on which any such statements are based. As a result of these
factors, the events described in the forward-looking statements contained in
this release may not occur.



                      This information is provided by RNS
            The company news service from the London Stock Exchange
END
NRAQDLFFVXBLBBD

Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Jun 2024 to Jul 2024

Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Jul 2023 to Jul 2024